Growing Role of Chinese Pharmaceutical Firms in Global Supply Chains

Why It Matters

The rise of Chinese biotech accelerates drug development timelines and lowers costs, forcing global pharma to partner with Chinese firms or risk losing competitive advantage.

Key Takeaways

• Chinese biotech firms supplied 46% of new drug candidates 2025.
• Faster, cheaper clinical trials attract global pharma to China.
• Oncology ADC licensing deals reached $30 billion in 2024.
• Chinese chemists dominate Nature Index chemistry contributions over US.
• Private equity fuels biotech growth, expecting future breakthrough.

Summary

The video highlights how Chinese biotech firms are reshaping global drug supply chains, with Shanghai’s “Pharma Valley” emerging as a hub. Goldman Sachs data show that 46% of new drug molecules entering human trials in the first half of 2025 originated from Chinese companies, underscoring a rapid shift in innovation geography.

Speed and cost are the primary drivers. A massive domestic patient pool enables rapid recruitment, cutting trial timelines, while development expenses are markedly lower than in the United States. This advantage has translated into a surge of out‑licensing deals, especially in oncology, where antibody‑drug conjugate (ADC) agreements in 2024 totaled $30 billion—three times the value of comparable U.S. deals.

Industry veteran Ray Lim notes, “Clinical trials actually run pretty quickly in the Chinese market,” and cites the lower cost structure. Shanghai‑based Duality Bio, a five‑year‑old player, has already partnered with GSK and BioNTech to commercialize ADCs abroad. The Nature Index shows China now contributes three times more chemistry papers than the U.S., reflecting the technical expertise that underpins ADC scale‑up.

For multinational pharmaceutical companies and investors, the trend signals a strategic imperative to engage Chinese innovators, either through licensing or joint ventures. Private‑equity funds have been betting on the sector for a decade, anticipating that biotech breakthroughs will become a new engine of China’s economic growth and reshape global drug pipelines.

Original Description

The next time you take a new prescription drug, there’s a chance it came from a lab in China. It’s estimated that China is now one of the biggest sources of new drug candidates that go into human trials globally. CNA’s Tan Yew Guan reports from Shanghai.